The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD severity into four grades based on a patient's postbronchodilator forced expiratory volume in 1 second (FEV 1 
Question 3
Answer: c. Until recently, the available LABAs were salmeterol (administered twice daily) and formoterol (usually administered twice daily). Several bronchodilators with a longer duration of action that allow once-daily administration have been developed. Those already licensed in the UK as single drug inhalers include the LAMAs glycopyrronium (Seebri Breezhaler), tiotropium (Spiriva) and umeclidinium (Incruse), and the LABA indacaterol(Onbrez Breezhaler). The LABA vilanterol is available in combination with umeclidinium (Anora Ellipta) or fluticasone furoate (Relvar Ellipta). dtb.bmj.com DTB CME/CPD | Produced in association with BMJ Learning DTB CME/CPD Answers Olodaterol-another LABA for COPD Answer: c. Pooled evidence from the 48-week studies showed that the most common adverse effects for olodaterol 5µg included nasopharyngitis (11%), upper respiratory tract infection (8.2%), bronchitis (4.7%), COPD exacerbations (26%), cough (4.2%), and dyspnoea (4.0%).
In the pooled results of the pivotal phase III studies, what were the most common adverse effects (>4%) 
Question 4
Answer: c. Olodaterol 5µg compared with placebo: difference in trough FEV 1 =78±21mL (p=0.0002) and 53±19mL (p<0.01) for studies 1222.13 and 1222.14, respectively. Suggested minimum clinically important difference for FEV 1 =100-140mL.
